GlassScriptPhysician profile
Albert L Tydings
NPI 1952364705
$4,646.22
in general payments reported to CMS, 2019-2025
39 companies · $912 in 2025
The $912 reported for 2025 was more than what 83% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $376 · 2021: $730 · 2022: $1,124 · 2023: $770 · 2024: $478 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,047 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,046.82 |
| Education | $113.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,214.56 | 2019-2025 | Lo Loestrin Fe, Orilissa, Liletta |
| Mayne Pharma Commercial LLC | $973.88 | 2021-2025 | |
| Astellas Pharma US INC | $561.40 | 2023-2025 | Veozah, Myrbetriq |
| Aspira Women'S Health INC | $187.98 | 2021-2022 | |
| Therapeuticsmd, INC. | $177.22 | 2020-2022 | |
| Evofem Biosciences, INC. | $165.45 | 2021-2025 | Phexxi, Solosec, Phexx |
| Millicent US INC | $125.31 | 2019-2025 | Intrarosa, Femring, Femlyv |
| Hologic Sales and Service, LLC | $122.78 | 2020-2025 | Aptima |
| Ascend Therapeutics US, LLC | $95.11 | 2022-2023 | |
| Avion Pharmaceuticals | $93.00 | 2020-2023 | Balcoltra |
| Merck Sharp & Dohme LLC | $92.58 | 2019-2025 | |
| Scynexis, INC. | $90.69 | 2022 | |
| Organon LLC | $82.14 | 2021-2023 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $77.29 | 2019-2025 | |
| Pfizer INC. | $63.79 | 2022-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $63.42 | 2021-2023 | Twirla |
| Mission Pharmacal Company | $59.09 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $54.58 | 2024-2025 | Myfembree |
| Mylan Pharmaceuticals INC. | $45.18 | 2021-2022 | |
| Biom'Up France Sas | $43.45 | 2021 | |
| Exeltis, USA INC. | $41.12 | 2021-2025 | Slynd |
| Daiichi Sankyo INC. | $33.92 | 2019 | |
| Lupin INC. | $28.97 | 2019-2020 | |
| Urovant Sciences INC | $28.00 | 2022 | |
| Amag Pharmaceuticals, INC. | $21.66 | 2019 | |
| Novo Nordisk INC | $21.03 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $19.67 | 2024 | Exparel |
| Sage Therapeutics, LLC | $18.11 | 2025 | Zurzuvae |
| Currax Pharmaceuticals LLC | $17.23 | 2025 | Onzetra Xsail, Contrave |
| Lilly USA, LLC | $15.28 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $12.33 | 2022 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Tydings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.